KRAS and non-small cell lung carcinoma: Our data demonstrate that plasma KRAS G12/G13 MAF is associated with unfavorable PFS ((HR) = 3.42, p < 0.001), and inferior OS ((HR) = 2.72, p < 0.001) in NSCLC patients.